Special Issue "Advances in Cancer Immunotherapy"
Deadline for Submission : Sep 30 2024
Special Issue Information
Special Issue on Cancer Immunotherapy
Cancer immunotherapy has revolutionized the treatment landscape for various cancers, leveraging the body's immune system to fight malignancies. This special issue aims to bring together cutting-edge research, reviews, and clinical studies that highlight the latest advancements and challenges in cancer immunotherapy.
Scope and Topics
This special issue invites submissions on, but not limited to, the following topics:
- Immune checkpoint inhibitors
- CAR-T cell therapy
- Tumor-infiltrating lymphocytes (TILs)
- Cancer vaccines
- Oncolytic viruses
- Combination therapies (immunotherapy with chemotherapy, radiotherapy, etc.)
- Biomarkers for immunotherapy response
- Mechanisms of immune resistance
- Novel targets and agents in immunotherapy
Submission Guidelines
Authors are invited to submit original research articles, reviews, and clinical studies that contribute to the field of cancer immunotherapy. All submissions will undergo a rigorous peer-review process.
Manuscript Submission:
- Deadline for Submissions: September 2024
- Submission Portal: www.immunologyresearchjournal.com/submission
- Manuscripts should be formatted according to the journal's guidelines www.immunologyresearchjournal.com/manuscript-guidelines.
- Ensure all co-authors have approved the manuscript and agree with its submission.
Keywords
Cancer Immunotherapy, Immune Checkpoint Inhibitors, CAR-T Cell Therapy, Tumor-Infiltrating Lymphocytes (TILs), Cancer Vaccines, Oncolytic Viruses, and Combination Therapies. It also focuses on Immunotherapy Biomarkers, Immune Resistance Mechanisms, Novel Immunotherapeutic Targets, Immuno-Oncology, and Precision Medicine in Immunotherapy. Other important areas include Immune Evasion, Clinical Trials in Immunotherapy, Adoptive Cell Transfer, Cytokine Therapy, Checkpoint Blockade, Immune Modulation, Antitumor Immunity, and Translational Immunotherapy. The issue explores Immunogenic Cell Death, Immune-Related Adverse Events, Neoantigens, Tumor Microenvironment, PD-1/PD-L1 Inhibitors, CTLA-4 Inhibitors, Immune Surveillance, Personalized Cancer Therapy, Immunotherapy Response, and Preclinical Immunotherapy Studies.